|
1
|
Citron ML, Berry DA, Cirrincione C, Hudis
C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R,
Ingle JN, et al: Randomized trial of dose-dense versus
conventionally scheduled and sequential versus concurrent
combination chemotherapy as postoperative adjuvant treatment of
node-positive primary breast cancer: First report of intergroup
trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol.
21:1431–1439. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jones SE, Savin MA, Holmes FA,
O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE,
Bordelon JH, Kirby R, et al: Phase III trial comparing doxorubicin
plus cyclophosphamide with docetaxel plus cyclophosphamide as
adjuvant therapy for operable breast cancer. J Clin Oncol.
24:5381–5387. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG). Increasing the dose intensity of
chemotherapy by more frequent administration or sequential
scheduling: A patient-level meta-analysis of 37 298 women with
early breast cancer in 26 randomised trials. Lancet. 393:1440–1452.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
NCCN Hematopoietic Growth Factors:
Short-term recommendations specific to issues with COVID-19
(SARS-CoV-2). https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf.
Accessed June 12, 2020.
|
|
5
|
Long L, Zeng X, Zhang X, Xiao W, Guo E,
Zhan W, Yang X, Li C, Wu C, Xu T, et al: Short-term outcomes of
COVID-19 and risk factors for progression. Eur Respir J.
55(2000990)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S,
Huang H, Zhang L, Zhou X, Du C, et al: Risk factors associated with
acute respiratory distress syndrome and death in patients with
coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern
Med. 180:934–943. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo
Q, Ji R, Wang H, Wang Y and Zhou Y: Prevalence of comorbidities and
its effects in patients infected with SARS-CoV-2: A systematic
review and meta-analysis. Int J Infect Dis. 94:91–95.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yang AP, Liu JP, Tao WQ and Li HM: The
diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19
patients. Int Immunopharmacol. 84(106504)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Eyles JL, Hickey MJ, Norman MU, Croker BA,
Roberts AW, Drake SF, James WG, Metcalf D, Campben IK and Wicks IP:
A key role for G-CSF-induced neutrophil production and trafficking
during inflammatory arthritis. Blood. 112:5193–5201.
2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hamilton JA and Achuthan A: Colony
stimulating factors and myeloid cell biology in health and disease.
Trends Immunol. 34:81–89. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Guilliams M, De Kleer I, Henri S, Post S,
Vanhoutte C, De Prijck S, Deswarte K, Malissen B, Hammad H and
Lambrecht BN: Alveolar macrophages develop from fetal monocytes
that differentiate into long-lived cells in the first week of life
via GM-CSF. J Exp Med. 210:1977–1992. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Trapnell BC, Nakata K, Bonella F, Campo I,
Griese M, Hamilton J, Wang T, Morgan C, Cottin V and McCarthy C:
Pulmonary alveolar proteinosis. Nat Rev Dis Primers.
5(16)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Favalli EG and Caporali R: GM-CSF in the
treatment of COVID-19: A new conductor in the pathogenesis of
cytokine storm? Lancet Rheumatol. 2(e448)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nawar T, Morjaria S, Kaltsas A, Patel D,
Perez-Johnston R, Daniyan AF, Mailankody S and Parameswaran R:
Granulocyte-colony stimulating factor in COVID-19: Is it
stimulating more than just the bone marrow? Am J Hematol.
95:E210–E213. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lang FM, Lee KM, Teijaro JR, Becher B and
Hamilton JA: GM-CSF-based treatments in COVID-19: Reconciling
opposing therapeutic approaches. Nat Rev Immunol. 20:507–514.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Komuczki J, Tuzlak S, Friebel E, Hartwig
T, Spath S, Rosenstiel P, Waisman A, Opitz L, Oukka M, Schreiner B,
et al: Fate-mapping of GM-CSF expression identifies a discrete
subset of inflammation-driving T helper cells regulated by
cytokines IL-23 and IL-1β. Immunity. 50:1289–1304.e6.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
De Luca G, Cavalli G, Campochiaro C,
Della-Torre E, Angelillo P, Tomelleri A, Boffini N, Tentori S,
Mette F, Farina N, et al: GM-CSF blockade with mavrilimumab in
severe COVID-19 pneumonia and systemic hyperinflammation: A
single-centre, prospective cohort study. Lancet Rheumatol.
2:e465–e473. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mehta P, Porter JC, Manson JJ, Isaacs JD,
Openshaw PJM, McInnes IB, Summers C and Chambers RC: Therapeutic
blockade of granulocyte macrophage colony-stimulating factor in
COVID-19-associated hyperinflammation: Challenges and
opportunities. Lancet Respir Med. 8:822–830. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lev S, Gottesman T, Sahaf Levin G,
Lederfein D, Berkov E, Diker D, Zaidman A, Nutman A, Ber TI, Angel
A, et al: Real-time IP-10 measurements as a new tool for
inflammation regulation within a clinical decision support protocol
for managing severe COVID-19 patients. medRxiv:
2020.07.21.20158782, 2020. doi: https://doi.org/10.1101/2020.07.21.20158782.
|
|
20
|
Brunetti O, Derakhshani A, Baradaran B,
Galvano A, Russo A and Silvestris N: COVID-19 infection in cancer
patients: How can oncologists deal with these patients? Front
Oncol. 10(734)2020.PubMed/NCBI View Article : Google Scholar
|
